In conclusion, inhibition of PTGR2 is a new therapeutic approach to treat diabetes and obesity through increasing endogenous PPARγ ligands while avoiding side effects including increased adiposity, fluid retention, and osteoporosis. The gene discussed is PTGR2; the disease is obesity due to melanocortin 4 receptor deficiency.